Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells.
A recombinant form of human migration inhibitory factor (rMIF) obtained from COS-1 cells transfected with MIF-specific cDNA is able to activate cultured human peripheral blood monocytes and monocyte-derived macrophages, in a dose-dependent manner to become cytotoxic for tumor cells in vitro. The cytotoxicity exhibited by macrophages treated with rMIF is > or = 30% above that of cells incubated with control supernatants or with media and peaks 72 hr after the addition of tumor targets. rMIF also induces macrophages to produce tumor necrosis factor (TNF-alpha) and interleukin-1 beta (IL-1 beta). These results demonstrate that rMIF is able to modulate macrophage functions and plays a role in cell-mediated immune response.
Pozzi
L A
LA
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Weiser
W Y
WY
D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007961:Leukocyte Migration-Inhibitory Factors / Q000494:pharmacology*; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D007961:Leukocyte Migration-Inhibitory Factors; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D006861:Hydrogen Peroxide